30 results about "Murine embryo" patented technology

The invention belongs to the field of medicines, and relates to a compound derived from Sinkiang lithospermum, a preparation method thereof and application of the compound in prevention and treatment of cardiovascular diseases. Specifically, the invention discloses a monoterpene benzoquinone derivative with a novel structure in Sinkiang lithospermum, a preparation method of the monoterpene benzoquinone derivative and application of the compound in preparation of anti-myocardial injury drugs. An in-vitro anti-myocardial cell injury activity experiment proves that the compound has a remarkable protection effect on isoprenaline (ISO)-induced H9C2 cell (rat embryo myocardial cell) injury and hypoxia-reoxygenation-induced H9C2 myocardial cell injury. The result shows that the compound can be used for preparing the anti-cardiovascular disease medicine.

The invention discloses an establishment method and a verification method of a hydrogen peroxide induced mouse autism model, and relates to the technical field of medical biologication.The establishment method of the hydrogen peroxide induced mouse autism model comprises the following steps that a hydrogen peroxide solution is injected into the abdominal cavity of a pregnant mouse, hydrogen peroxide induction is conducted, and the mouse autism model is obtained. And obtaining a hydrogen peroxide induced offspring mouse, namely the mouse autism model. Hydrogen peroxide is used for near intraperitoneal injection of a female mouse during pregnancy, the oxidative stress state of the female mouse during pregnancy and the oxidative stress state of an offspring mouse embryo are induced through independent hydrogen peroxide, and obvious immune response of the female mouse is not caused, so that an ASD mouse model specifically induced by oxidative stress is formed; the obtained ASD offspring mouse has a remarkable ASD phenotype, but does not show obvious dyskinetic disorder.

The invention provides a genome editor enDelIscB and a genome editor enDelIscB-T5E based on an IscB system, and further provides a base editor ICBE and a base editor IABE based on the enDelIscBD60A. According to the invention, a genome editor and a base editor which are more compact in size and higher in cleavage activity and insertion / deletion efficiency are realized by optimizing a single mutation site of the activity of a DelIscB protein cleavage plasmid, an optimized variant of the DelIscB protein and an optimized sgRNA variant of the DelIscB. According to the present invention, it is verified that the albinism model is efficiently constructed by using the enDelIscB editor and the enDelIscB-T5E editor through micro-injection of the mouse embryo, such that the enDelIscB editor and the enDelIscB-T5E editor have great potential in the field of genome editing.

The present invention discloses an Ush1c gene enhancer and its application, belonging to the field of genetic engineering, and the nucleotide sequence of the enhancer is shown in SEQ ID No. 1. The mouse embryo microinjection system is used to confirm that the sequence is an enhancer, which can significantly enhance the transcription activity of the EGFP protein gene in the inner ear. Compared with other sequences of similar size, the enhancer sequence fragment can drive the reporter gene or Ush1c to express significantly in the inner ear, and specifically express it in inner and outer hair cells, and is suitable for recombinant DNA, vectors or adenovirus and other biological materials, and is used to promote the transcription of EGFP gene or other genes in the inner ear.

The invention belongs to the technical field of biomedicine, and relates to a method for constructing a mouse embryo-derived hypothalamic organ model and application, the invention proposes that a mouse embryo is used for constructing a hypothalamic organ for the first time, and the mouse embryo has a definite development time sequence and genetic operability; the naturally retained vascular endothelial cells and multilineage precursor cells provide unique advantages for constructing a three-dimensional organ containing multiple nucleuses such as a preoptic region, a paraventricular nucleus, an arcuate nucleus and a supraoptic nucleus, and the model not only breaks through the nucleus coverage limitation of the existing iPSCs organ, but also can be used for constructing the three-dimensional organ containing multiple nucleuses such as the preoptic region, the paraventricular nucleus, the arcuate nucleus, the supraoptic nucleus and the like by reconstructing a nerve-blood vessel unit. High-fidelity simulation of complex physiological functions of the hypothalamus is realized, and an irreplaceable technical platform is provided for mechanism analysis of neuroendocrine diseases and high-throughput screening of drugs.

The invention relates to the technical field of in-vitro embryo culture, in particular to an in-vitro culture method and culture system of a mouse embryo. The method comprises the following steps: dropwise adding hydrogel onto a PDMS substrate, putting at least one, at least two, at least three, at least five or more embryos into hydrogel liquid drops, curing, and then adding a culture solution for embryo culture; wherein the Young modulus of the cured hydrogel liquid drops is 10 to 100 Pa. The in-vitro culture system comprises a PDMS (Polydimethylsiloxane) substrate and hydrogel liquid drops arranged on the PDMS substrate, and the hydrogel liquid drops are used for coating the mouse embryo; wherein the Young modulus of the cured hydrogel liquid drops is 10 to 100 Pa. When the method and the system are used for in-vitro embryo culture of mice, the embryos can normally develop and have a relatively high development rate within the in-vitro culture time of 9 days during in-vitro embryo culture.

The present invention discloses a Mitf gene enhancer and its application in improving the gene-specific expression of cochlear stria vascular cells, and relates to the field of gene expression and regulation technology. The nucleotide sequence of the enhancer is shown in SEQ ID No. 1. The mouse embryo microinjection system was used to confirm that the sequence is an enhancer, which can significantly enhance the transcription activity of the EGFP protein gene in the cochlear stria vascular cells. Compared with other sequences of similar size, the enhancer sequence fragment can drive the reporter gene or Mitf to be specifically expressed in the cochlear stria vascular cells and the expression level is significantly enhanced. The enhancer is suitable for biological materials such as recombinant DNA, vectors or adenoviruses, and is used to promote the transcription of the EGFP gene or other genes in the cochlear stria vascular cells.

The invention discloses the use of tributyrin as an additive for embryo in vitro development culture medium, and belongs to the technical field of animal reproductive biology. The invention applies tributyrin as an additive to mouse embryo in vitro development culture medium for the first time, and the tributyrin can significantly improve the blastocyst rate, reduce the ROS content in the embryo, improve the mitochondrial membrane potential in the embryo, improve the ATP level in the embryo and the expression of antioxidant genes, improve the DNA methylation and histone modification level in the embryo, and promote the embryo in vitro development; and tributyrin, as a natural antioxidant and epidrug, is safe and has no toxic side effects, is cheap and easy to obtain, does not need to replace the culture medium during the entire development and culture process, and is simple to operate; the tributyrin provides strong support for in vitro embryo engineering technologies such as the efficient development of embryos in human assisted reproductive technology, mammalian fertilized embryos, parthenogenetic embryos and somatic cell cloned embryos, and has good application prospects.

This invention discloses a method for establishing and validating a hydrogen peroxide-induced mouse autism model, relating to the field of medical biotechnology. The method for establishing the hydrogen peroxide-induced mouse autism model includes the following steps: injecting the hydrogen peroxide solution into the peritoneal cavity of pregnant mice to induce hydrogen peroxide, resulting in offspring mice with hydrogen peroxide induction, i.e., the mouse autism model. This invention uses near-peritoneal injection of hydrogen peroxide during the gestational period of the mother mouse, inducing oxidative stress in both the pregnant mother mouse and the offspring embryo through hydrogen peroxide alone, without causing a significant immune response in the mother mouse. Therefore, an oxidative stress-specifically induced ASD mouse model is formed. The resulting ASD offspring mice exhibit significant ASD phenotypes but do not show obvious motor impairment.

This invention belongs to the field of gene editing and epigenetics technology, and discloses a method based on dCasRx-FTO for m 6 A. Editing system and its recombinant expression plasmid, cell model and its application; this invention first constructs an m based on dCasRx-FTO. 6 The A-editing system, namely the dCasRx-FTO fusion protein, utilizes catalytically inactivated CasRx (dCasRx) as a highly specific RNA guidance scaffold to fuse with m 6 A demethylase FTO enables the targeting of a specific region m 6 Targeted removal of A-modification. Building upon this, the present invention further obtains monoclonal mouse embryonic stem cells (mESCs) stably expressing the dCasRx-FTO fusion protein. Combined with an sgRNA library targeting a specific set of transcripts, high-throughput screening can be performed on embryonic stem cells containing the 2C-like pluripotency reporter gene MERVL::tdTomato, thereby identifying key m-modification inhibitors suppressing the pluripotency state of mESCs at the transcriptome level. 6 A modification site, thus enabling its use to reveal m 6 The key role of A-modified targets in the regulation of stem cell pluripotency.

The invention discloses a Pcdh15 gene enhancer sequence and application thereof, and belongs to the field of gene engineering, and the nucleotide sequence of the enhancer is shown as SEQ ID No.1. A mouse embryo microinjection system is used for verifying that the sequence is an enhancer, and the transcriptional activity of EGFP protein genes in hair cells can be remarkably enhanced in inner ears. Compared with other sequences with similar sizes, the enhancer sequence fragment can drive the expression ability of a reporter gene or a Pcdh15 gene to be obviously enhanced in inner ear hair cells, is specifically expressed in inner and outer hair cells, is suitable for biological materials such as recombinant DNA (Deoxyribonucleic Acid), vectors or adenoviruses and the like, and has a wide application prospect. The method is used for promoting transcription of EGFP genes or other genes in internal and external hair cells of inner ears.

The invention discloses application of ethyl caffeate in preparation of heart and nerve protection medicines, and belongs to the technical field of biological medicines. Models of rat embryo myocardial cell injury caused by oxygen-glucose deprivation and mouse microglial cell injury caused by lipopolysaccharide are respectively constructed, and related indexes such as inflammation, oxidative stress and cell apoptosis are evaluated; it is proved that ethyl caffeate has an obvious protection effect on ischemic and hypoxic myocardial cells and inflammation-damaged glial cells, and can be used for preparing heart and nerve protection drugs.

The present invention relates to the application and method of the PARP inhibitor Veliparib in screening BRCA1 heterozygous mutant embryos. The present invention applies a PARP inhibitor Veliparib with low capture effect to the screening of BRCA1 heterozygous mutant mouse embryos. Through animal experiments, a new use of 7.5 μM Veliparib in selectively blocking the development of BRCA1 heterozygous embryos is developed, blocking the inheritance of the BRCA1 pathogenic gene and avoiding the birth of BRCA1 heterozygotes in the offspring. Compared with the currently clinically applied PGT-M technology, the present invention breaks through the thinking of screening mutant embryos using gene sequences, and innovatively and more directly and efficiently screens BRCA1 heterozygous embryos with insufficient homologous recombination function from the protein function level, with the characteristics of simple operation, high cost performance, small trauma and high accuracy.

The present invention provides a recombinant human type II collagen fragment, the amino acid sequence is shown in SEQ ID NO.2, and the coding gene sequence is shown in SEQ ID NO.1. The present invention also provides an expression vector and Pichia pastoris engineering bacteria comprising the above-mentioned recombinant human type II collagen fragment coding gene. At the same time, the present invention also provides a preparation and application of the above-mentioned recombinant human type II collagen fragment. The recombinant human type II collagen fragment of the present invention not only has a significant effect on promoting the proliferation and migration of human chondrocytes, but also shows excellent effects of promoting cell migration and promoting adhesion in human immortalized epidermal cells and mouse embryonic fibroblasts, and can be widely used in artificial bones, artificial cartilage, artificial corneas, vitreous bodies, wound repair materials, supporting biomaterials, medical cosmetic surgery, cosmetics and other fields.

The invention provides a culture method for promoting conversion of mouse embryonic stem cells into totipotent stem cells. The cells can be kept in a brand new form and subcultured under the condition. According to the method adopted by the invention, an inhibitor WM-3825 of 2 mu M H4K16ac is added into a DMEM (Dulbecco Modified Eagle Medium) with a culture medium composition of 10% fetal calf serum according to a proportion of 1: 1000, the mouse embryonic stem cells can be normally cultured and passaged, the change of the totipotent gene is detected through real-time fluorescent quantitative PCR (Polymerase Chain Reaction), the expression of the totipotent related gene Dux is found to be obviously increased, and the expression of the mouse embryonic stem cells is obviously improved. Flow cytometry detection shows that the proportion of the totipotent stem cells is remarkably increased, and AP dyeing shows that the pluripotency of the mouse embryonic stem cells is reduced. The method starts from cell culture, and the method is possibly suitable for research on conversion from pluripotency to totipotency of embryonic stem cells of other mammals including human. By adding a small-molecule inhibitor WM-3825 of H4K16ac, a brand-new method for promoting conversion from the mouse pluripotent stem cells to the totipotent stem cells is established, and the 2-cell period of mouse embryonic development can be simulated in vitro through the culture system. The invention provides a new method for the generation of the totipotent stem cells, deepens the understanding of people on different states of the stem cells, and provides a new perspective for understanding an epigenetics mechanism between the conversion of the totipotent stem cells and the conversion of the pluripotent stem cells.

The invention discloses an induced differentiation and identification method for obtaining nerve cells in different stages from mouse embryonic stem cells, and relates to the technical field of biology. The induced differentiation and identification method comprises the following steps: inoculating mouse embryonic stem cells into a culture container, and carrying out pluripotent maintenance culture by adopting a pluripotent maintenance culture medium; after the pluripotency maintenance culture is completed, discarding the culture medium, washing, and adding a nerve induced differentiation culture medium for nerve induced differentiation culture; in the process of nerve induced differentiation culture, gene marker and protein marker detection is carried out to obtain nerve cells in different stages. According to the induced differentiation and identification method provided by the invention, efficient and controllable differentiation of the mouse embryonic stem cells to the neural pedigree can be realized through standardized sequential control and a multi-dimensional verification system. According to the invention, an efficient and reliable cell source and a technical platform are provided for the research of a neurodevelopment mechanism and the construction of a neurodegenerative disease model.

The method of generating multipotent stem cells is a method for producing and / or expanding multipotent stem cells by delivering at least one reprogramming protein into somatic cells. The at least one reprogramming protein includes a Master Regulator (MR) protein, which may be BAZ2B, ZBTB20, ZMAT1, CNOT8, KLF12, DMTF1, HBP1, or FLI1. The bromodomain protein BAZ2B, in particular, was identified by first generating bi-species heterokaryons by fusing Tcf7l1− / − murine embryonic stem cells (ESCs) with human B-cell lymphocytes. Reprogramming of the B-cell nuclei to a multipotent state was tracked by human mRNA transcript profiling at multiple timepoints. Interrogation of a human B-cell regulatory network with gene expression signatures collected from such reprogramming time series identified eight candidate Master Regulator proteins, which were validated in human cord blood-derived hematopoietic progenitor and lineage-committed cells.

The invention relates to the technical field of monoclonal antibodies and medicines, and discloses a monoclonal antibody for inhibiting damage of Zika virus to blood fetal / blood testis barrier and application thereof, the monoclonal antibody is a monoclonal antibody aiming at ITGB4 antigen, and the amino acid sequence comprises a heavy chain variable region and a light chain variable region; the heavy chain variable region comprises a heavy chain CDR1 as shown in SEQ ID NO.3, a heavy chain CDR2 as shown in SEQ ID NO.4 and a heavy chain CDR3 as shown in SEQ ID NO.5; the light chain variable region comprises a light chain CDR1 as shown in SEQ ID NO.6, a light chain CDR2 as shown in SEQ ID NO.7 and a light chain CDR3 as shown in SEQ ID NO.8; according to the scheme, the monoclonal antibody 7C3 can be combined with a ZIKV host cell receptor ITGB4, so that the ZIKV virus is effectively inhibited from infecting host cells, and the survival rate of Ifnar1- / -mouse A129 infected with ZIKV is increased. The 7C3 antibody in the scheme can effectively inhibit damage of ZIKV virus infection to pregnant mouse embryos or male mouse testis.

The invention relates to the technical field of biological medicines, and discloses an application of phosphodiesterase PDE4D in preparation of a medicine for treating virus infectious diseases, and an application of a phosphodiesterase PDE4 inhibitor or a salt thereof in preparation of a medicine for treating virus infectious diseases for a long time. Experiments prove that the expression of PDE4D can significantly inhibit the replication of VSV, HSV, PR8 and other viruses; the cell death can be obviously inhibited; the inflammatory response caused by virus infection can be inhibited; the PDE4 inhibitor can induce the expression of PDE4D after long-term treatment; long-term treatment with the PDE4 inhibitor can significantly inhibit embryo loss of pregnant rats caused by virus infection; long-term treatment with the PDE4 inhibitor can reduce viral load of lung and placenta tissues of pregnant rats and pathological changes caused by viral infection.

The invention relates to the field of biological medicines, and discloses an embryonic mesenchymal stem cell-derived exosome, a preparation method thereof and an application of the embryonic mesenchymal stem cell-derived exosome as a protective agent in medicines for improving striae gravidarum of pseudopregnant rats. The medicine for improving the striae gravidarum of the pseudopregnant mouse is prepared from the embryonic mesenchymal stem cell-derived exosome. The construction method of the protective agent model for verifying the striae gravidarum of the pseudopregnant mouse comprises the following steps: modeling the pseudopregnant mouse, and then subcutaneously injecting the mouse embryo mesenchymal stem cell-derived exosome into the mouse. The research finds that the mouse embryo mesenchymal stem cell-derived exosome can be used for preparing the medicine for improving the stretch marks of the pseudopregnant mouse, so that the situation of abdominal skin fiber fracture and injury is improved, and abdominal elastic fiber fracture caused by pregnancy and other reasons is prevented and protected. The method is high in treatment sensitivity and remarkable in improvement effect. The method has good application value and popularization prospect.

The invention provides a mouse embryo cryopreservation and resuscitation method. The mouse embryo cryopreservation and resuscitation method comprises the following steps that a cryopreservation solution A and a cryopreservation solution B are used for cryopreservation of mouse embryos; a resuscitation solution C and an operation solution D are used for resuscitating the mouse embryo; wherein the cryopreservation solution A comprises the following components: 1-15v / v% of dimethyl sulfoxide and the balance of M2 embryo culture solution; the cryopreservation solution B comprises the following components: 5-30v / v% of dimethyl sulfoxide, 0.01-0.1 g / ml of acetamide, 10-40v / v% of propylene glycol and the balance of an M2 embryo culture solution; the resuscitation solution C comprises the following components: 0.1-0.4 M sucrose and the balance of M2 embryo culture solution; the operating solution D comprises an M2 embryo culture solution. The dimethyl sulfoxide, the acetamide and the propylene glycol are jointly used, so that the toxicity of the dimethyl sulfoxide is reduced, and the freezing efficiency is improved. A permeable cryoprotectant is selected for embryo freezing, the concentration of the cryoprotectant is gradually increased through a two-step balance method, and a non-permeable cryoprotectant is selected for resuscitation, so that permeation shock caused by unfreezing and rewarming is reduced.

The invention belongs to the technical field of biology, and particularly relates to a male embryonic stem cell of a BALB / c mouse strain and application of the male embryonic stem cell. The name of the male embryonic stem cell is mouse embryonic stem cell MX4, and the male embryonic stem cell is classified and named as mouse embryonic stem cell, and is preserved in Guangdong Microbial Culture Collection Center on the fifth floor, No.59 building, No.100 Courtyard, Xianlie Middle Road, Guangzhou City on July 10, 2024, and the preservation number is GDMCC No.64854. The method has high tetraploid efficiency (the efficiency of a tetraploid compensation technology), and can be used for preparing mouse chimera embryos or mice.

This invention discloses a method for inducing mouse embryonic stem cells to transition to a pluripotent state using H2BC21 and its application, belonging to the fields of molecular biology and stem cell engineering technology. By constructing an interference vector targeting the H2BC21 gene, packaging it with lentivirus, and infecting mouse embryonic stem cells, the expression of the H2BC21 gene is knocked down, and embryonic stem cell lines with stable low expression of H2BC21 are obtained through screening. This invention is the first to discover that H2BC21 is a core negative regulator of mammalian embryonic stem cell pluripotency. After knocking down H2BC21, the expression of pluripotency core genes Nanog, Oct4, and Sox2 is downregulated, while the expression of pluripotency core genes Zscan4b, Usp17la, and Tmem92 is upregulated. The cells exhibit molecular characteristics similar to 2-cell phase cells, successfully achieving the transition from pluripotency to a pluripotent state.

The present invention discloses a rat embryo cryopreservation pretreatment solution, which is composed of a basal culture medium, 95 to 110 mL / L of propylene glycol, 0.8 to 1.5 g / L of polyvinyl alcohol, and an appropriate amount of antibiotics. In addition, the present invention also provides a rat embryo cryopreservation-resuscitation system comprising the aforementioned rat embryo cryopreservation pretreatment solution. The present invention can break through the bottleneck of rat germplasm resource preservation. The application of the supporting rat embryo cryopreservation-resuscitation system can enable the cryopreservation-resuscitation of rat embryos and subsequent artificial assisted reproduction to proceed smoothly, especially for rat resources with homozygous genotypes. The several months required for natural reproduction are greatly reduced to SPF-level offspring within one month, and rat resources with specific genotypes or genetic modifications can be quickly obtained.

The utility model relates to the technical field of mouse embryo culture, in particular to a mouse embryo incubator with a temperature control function, which comprises a rack and the like, the rack is a support carrier of the mouse embryo incubator and is a square cabinet, and a plurality of storage compartments are arranged in the rack at intervals in an array manner; the hatching box bodies are installed in the compartments of the rack, and openings for placing mouse culture dishes are formed in the front sides of the hatching box bodies; the fixing blocks are symmetrically and fixedly arranged on the two sides, close to the opening, of the front side of the incubation box body. The motor drives the lead screw to adjust the position of the heat insulation plate, the interior of the rack can be flexibly divided into two incubation compartments with different temperatures, independent temperature control over each compartment is achieved through the cooperation of the miniature air conditioners on the two sides, the most suitable temperature environment is provided according to different development stages of mouse embryos, and the incubation efficiency is improved. The success rate and the consistency of embryo culture are improved.

The invention belongs to the technical field of animal models, and particularly relates to a preparation method for constructing a rat embryo implantation failure model based on streptococcus agalactiae. The method comprises the following steps: culturing a streptococcus agalactiae strain with the number of BNCC336970 by using a solid culture medium containing sheep blood, adjusting the concentration of a bacterial solution to 1 * 10 < 8 > CFU / mL, and carrying out vaginal perfusion on an SPF-grade female SD rat every day for 21 days continuously. And after the perfusion is finished, the female mouse is mated with the male mouse at the early oestrus stage, the detected vaginal suppository is marked as the 0.5 th day of pregnancy, the mouse is killed at the 7.5 th day of pregnancy, and the model is evaluated by counting the embryo implantation quantity and detecting the expression level of endometrial tissue receptivity factors MMP9 and VEGF (Vascular Endothelial Growth Factor). A clinical pathogen pathogenic mechanism is simulated through a genital tract infection way for the first time, and the problem of physiological status deviation caused by traditional hormone intervention, immune agonists or genetic engineering methods is solved. The constructed model can stably induce the obvious reduction of the embryo implantation number and the reduction of endometrial receptivity, and provides a standardized tool for the pathological mechanism research of infectious embryo implantation failure and the screening of therapeutic drugs.

The utility model relates to the technical field of mouse embryo culture, in particular to a mouse embryo culture device which comprises a box body and a door plate, the box body is an assembly carrier of the culture device, an opening for placing a culture dish is formed in the front side face of the box body, and the door plate is hinged to the opening in the front side of the box body. A handle is mounted on the outer wall of the front side of the door plate; the motor is fixedly mounted on an inner bottom plate of the box body, and a convex rod is fixedly arranged on an output shaft of the motor; a hollow sleeve rod is fixedly connected to the bottom face of the rotating table, a sliding groove is formed in the side wall of the sleeve rod, and the rotating table is arranged on an output shaft of the motor through the sleeve rod. According to the utility model, the rotating table is driven by the motor to rotate slowly, and the culture dishes on the rotating table are intermittently shaken by combining the design of the concave-convex sliding rails, so that mechanical stimulation and flowing conditions similar to an in-vivo environment are created, and the development quality of embryos is favorably improved.

The invention discloses a method for constructing a rat embryo implantation failure model based on staphylococcus aureus, and belongs to the technical field of animal models. According to the method, ATCC23235 (purchased from ATCC with the strain number of ATCC 23235) staphylococcus aureus bacterial liquid (1 * 10 < 8 > CFU / mL, 200 [mu] L / mouse, and continuous 28 days) is perfused in vagina to induce SD rat embryo implantation number reduction and endometrial receptivity related factor expression reduction, and the pathological state of embryo implantation failure is successfully simulated. The model disclosed by the invention avoids limitation of hormone or gene intervention, is closer to a clinical infection mechanism, and is suitable for etiological research and therapeutic drug screening of embryo implantation failure.

This invention relates to an energy drug for treating mitochondrial damage under hypoxic conditions. The energy drug is the application of racemic scopolamine (Rac) in remodeling mitochondrial function. Hypoxic conditions include physiologically or pathologically induced hypoxia such as high altitude or vascular occlusion. This invention uses racemic scopolamine to treat hypoxic rat embryonic cardiomyocyte H9C2 and BALB / c mouse models, demonstrating that the compound has the characteristic of remodeling mitochondrial function under hypoxic conditions. It is a highly effective energy drug with promising clinical application prospects.

The present invention relates to the field of monoclonal antibodies and pharmaceutical technology, and discloses a monoclonal antibody for inhibiting the damage of Zika virus to the blood-fetal / blood-testis barrier and its application. The monoclonal antibody is directed against ITGB4 antigen, and the amino acid sequence includes a heavy chain variable region and a light chain variable region; the heavy chain variable region includes a heavy chain CDR1 as shown in SEQ ID NO. 3, a heavy chain CDR2 as shown in SEQ ID NO. 4, and a heavy chain CDR3 as shown in SEQ ID NO. 5; the light chain variable region includes a light chain CDR1 as shown in SEQ ID NO. 6, a light chain CDR2 as shown in SEQ ID NO. 7, and a light chain CDR3 as shown in SEQ ID NO. 8. The monoclonal antibody 7C3 of this scheme can bind to the ZIKV host cell receptor ITGB4, effectively inhibit the infection of ZIKV virus to host cells, and increase the expression of Ifnar1 ‑ / ‑ The survival rate of mouse A129 infected with ZIKV. And the 7C3 antibody in this scheme can effectively inhibit the damage of ZIKV virus infection to pregnant mouse embryos or male mouse testicles.